FDA’s Patient-Focused Drug Development Meetings Inspire Imitators
FDA likes the idea of advocacy groups convening their own meetings, but some stakeholders say the conversations need more depth.
You may also be interested in...
Patient experience will be incorporated into agency orphan grant reviews, and outside rare disease experts will help make decisions.
After conducting 24 disease-focused meetings in five years, FDA moving to next phase of patient interaction under new user fee cycle.
Patient Engagement Collaborative expected to invite stakeholders to discuss how patient interaction with FDA can improve.